Ranirestat

Overview

Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC 50 s of 11 nM and 15 nM for rat lens AR and recombinant human AR , respectively, and a K i of 0.38 nM for recombinant human AR . Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Aldose Reductase

Product Information

• Catalog No.: HY-15314
• CAS No.: 147254-64-6
• Molecular Formula: C17H11BrFN3O4
• Molecular Weight: 420.19
• Purity: 96.10%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.95 mM); Clear solution
• Availability: In-stock

Source

Original product source